Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2025. The document serves as a transaction notification regarding a sale of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
| Transaction Detail | Value |
|---|---|
| Instrument | Ordinary Shares of 31½ pence each (ISIN: GB00BN7SWP63) |
| Transaction Type | Sale |
| Volume | 29,763 shares |
| Price per Share | £15.4447 |
| Transaction Date | June 12, 2025 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It discloses a reduction in the shareholding of a specific executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. It is a routine disclosure of insider trading activity.
Key Facts for Investor Verification
- Executive Identity: The seller is Sally Jackson, SVP, Global Communications & CEO Office.
- Transaction Nature: This was an initial notification of a sale, not an amendment to a previous report.
- Market Context: The transaction occurred on the London Stock Exchange at a price of £15.4447 per share.
- Scope Limitation: This document does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.